ERBB2 and breast cancer: An analysis of the SEER database between 2019 and 2020, which included 320,124 BC women, showed that luminal A subtype was the most frequent, accounting for 73% of cases, followed by luminal B (11%), TNBC (11%) and HER2-enriched (5%) (Acheampong et al. 2020).